Boğaziçi CT3
Boğaziçi University Center for Targeted Therapy Technologies (Boğaziçi CT3) Platforms are interdisciplinary research and production infrastructures designed to develop innovative solutions in biomedical research and health technologies.
Each platform has a distinct focus area, including implantable and in-body devices, cell- and protein-based therapies, nanomedicine technologies, biomaterials, and microalgae biotechnology. Supported by advanced analytical units, cleanroom facilities, and experimental imaging capabilities, this ecosystem produces outputs across a wide range—from novel medical devices and functional food products to nanomedicine candidates and cancer vaccines.
By aiming to translate research ideas into clinical applications and societal benefit, Boğaziçi CT³ Platforms aspire to become one of the leading centers in health technologies in Türkiye and worldwide.
The Nanomedicine Technologies Platform is a research and development infrastructure focused on targeted drug delivery systems and nanotechnology-based therapeutic approaches. Within the scope of the platform, research is carried out particularly on the development of nanoparticles capable of delivering smart therapies directly to the target site in cancer treatment, while targeted drug approaches for different diseases are also pursued. The platform is structured to support both research groups within the center and spin-off initiatives emerging from its innovation and entrepreneurship ecosystem.
One of the platform’s most prominent achievements is that one of Türkiye’s first drug candidates to reach the clinical stage was developed within this infrastructure. All non-GLP preclinical studies related to this lead candidate were conducted at the center. In this respect, the platform provides a strong research environment that supports the translation of scientific research into application and plays a pioneering role in the development of innovative nanomedicine solutions at both national and international levels.
For communication and further information, you may contact us via [email protected]
The Biomaterials Technologies Platform is an interdisciplinary research and development infrastructure that operates in close interaction with the Implantable Medical Device Technologies, Cell and Protein Technologies, and Nanomedicine Technologies platforms. Within the scope of the platform, biocompatible biomaterials are designed, prepared, characterized, and further developed for application-oriented use. These biomaterials are utilized in a wide range of areas including implantable medical device coatings, carrier systems for diagnostic applications, surfaces for protein immobilization, nanostructures for cell capture, wound dressings, and tissue engineering applications.
The platform is supported by the infrastructure of the Medical Device (Cleanroom) Unit and the Testing and Analysis Unit. This enables the integration of biomaterials into medical device and prototype development workflows, while also allowing comprehensive physical, chemical, microscopic, biological, and rheological characterization studies. In addition, the biocompatibility assessments and related analytical services provided through the Industrial Services Testing and Analysis Unit contribute directly to both academic research and industrial collaboration and product development processes. In this way, the platform serves not only as an enabling environment for advanced research, but also as a key convergence point for translational research and commercialization activities across other platforms.
For communication and further information, you may contact us via [email protected]
The Cell and Protein Technologies Platform conducts research and development activities in the fields of vaccine technologies, particularly cancer vaccines, cell-based approaches, and antigen delivery systems designed to enhance immunological efficacy. Within the scope of the platform, studies focus on the development of novel vaccine strategies for different diseases and organisms, as well as innovative carrier systems that strengthen immune responses. Positioned within Boğaziçi CT3’s targeted therapy technologies framework, the platform aims to contribute both to scientific knowledge generation and to translational research processes extending toward clinical application.
For communication and further information, you may contact us via [email protected]
The Implantable Medical Device Technologies Platform is a research and development infrastructure focused on the development of biomedical devices targeting specific sites within the body. One of the platform’s prominent areas of activity is the development of neuroprostheses and neuromorphic (brain-inspired) solutions, particularly for applications related to the brain and nervous system. In this context, the platform aims to support the local development, prototyping, and advancement of high-value smart medical devices toward more advanced stages of application.
Within Boğaziçi CT3’s targeted therapy technologies framework, the platform provides an integrated structure that supports translational research processes extending from concept to product. In addition, through the international collaboration environment established by NeurotechEU – European University of Brain and Technology, of which Boğaziçi University is a founding partner, the platform seeks to advance its research and technology development activities in interaction with Europe-wide networks. In this respect, the platform contributes both to scientific knowledge generation and to the commercialization potential of innovative biomedical devices.
For communication and further information, you may contact us via [email protected]
The Microalgae Biotechnology Platform is a research and development infrastructure focused on the screening of bioactive compounds derived from highly bioactive microalgae species, the characterization of candidate molecules, and their application-oriented development. Within the scope of the platform, the in vitro and in vivo activities of microalgae-derived bioactive molecules are demonstrated with the support of genomic, transcriptomic, metabolic, and proteomic analyses, with the aim of developing these molecules into active pharmaceutical ingredients that can be used in disease treatment. In line with these efforts, the platform seeks to develop innovative products primarily for the pharmaceutical and functional food sectors, as well as for related application areas.
For communication and further information, you may contact us via [email protected]